Fundraising Fox
Creyon Bio
Founded 2019 · 22 employees on LinkedIn · 7 known investors
Find your way into Creyon Bio
Sign up to see every warm intro you have to Creyon Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Creyon Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Creyon develops cell-specific therapeutics using aptamer-delivered oligonucleotides, engineering aptamers to deliver therapeutic payloads to immune cells and across the blood-brain barrier for immune-driven and CNS diseases, plus a splice-switching oligonucleotide program for late-onset Pompe disease. It pairs this delivery technology with an AI/ML nucleic acid engineering platform (NucleIQ) to design nucleic acid therapies.
Investors · 7
How we know: funding news · Not right? Tell us
How we know: a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: DCVC Bio's portfolio page · funding news · Not right? Tell us
How we know: funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: a partner's Signal profile · funding news · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeed and Series AMar 2022Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Creyon Bio do?
- Creyon develops cell-specific therapeutics using aptamer-delivered oligonucleotides, engineering aptamers to deliver therapeutic payloads to immune cells and across the blood-brain barrier for immune-driven and CNS diseases, plus a splice-switching oligonucleotide program for late-onset Pompe disease. It pairs this delivery technology with an AI/ML nucleic acid engineering platform (NucleIQ) to design nucleic acid therapies.
- Who are Creyon Bio's investors?
- Creyon Bio's investors include BioBrit, DCVC (Data Collective), DCVC Bio, Tenmile, Alexandria, Casdin Capital, Lux Capital.